USPTO Examiner SEITZ ANTHONY JOSEPH - Art Unit 1629

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19018788COMPOUNDS AS GLP-1R AGONISTSJanuary 2025June 2025Allow510YesNo
19018805COMPOUNDS AS GLP-1R AGONISTSJanuary 2025June 2025Allow510YesNo
19018817COMPOUNDS AS GLP-1R AGONISTSJanuary 2025June 2025Allow510YesNo
19018754COMPOUNDS AS GLP-1R AGONISTSJanuary 2025May 2025Allow510YesNo
19018773COMPOUNDS AS GLP-1R AGONISTSJanuary 2025May 2025Allow510YesNo
18434159SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOFFebruary 2024September 2024Allow720YesNo
18408663METHODS OF TREATING BACTERIAL INFECTIONSJanuary 2024June 2025Allow1711NoNo
18175630COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH ELEVATED ARGININE VASOPRESSIN LEVELSFebruary 2023November 2024Abandon2110NoNo
18172875TRIENTINE TETRAHYDROCHLORIDE AND A METHOD OF PREPARATION AND A PHARMACEUTICAL COMPOSITION THEREOFFebruary 2023February 2025Allow2330YesNo
18151265COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENTJanuary 2023March 2025Allow2730NoNo
18079904ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASEDecember 2022September 2024Allow2120NoNo
18061127THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTIONDecember 2022April 2024Allow1711NoNo
18007840PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFDecember 2022June 2025Allow3100NoNo
17984405PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERYNovember 2022July 2025Allow3240YesNo
18049547PIPERIDINYLPYRAZINE-CARBOXAMIDE COMPOUNDS FOR TREATING AND PREVENTING CANCER AND FOR DEGRADING BTKOctober 2022March 2025Allow2940NoNo
17954047COMPOUNDS AS GLP-1R AGONISTSSeptember 2022December 2024Abandon2621NoNo
17912842PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOFSeptember 2022April 2025Abandon3100NoNo
17929003PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITORAugust 2022June 2025Allow3410NoNo
17929007PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITORAugust 2022April 2025Allow3210NoNo
17792792IRAK4 INHIBITOR CRYSTAL AND PREPARATION METHOD THEREFORJuly 2022April 2025Allow3310NoNo
17810620TREATMENT OF ANEURYSMSJuly 2022March 2025Allow3231NoNo
17848554COMPOSITION FOR TREATING OR PREVENTING CLIMACTERIC DISORDERSJune 2022October 2024Abandon2820NoNo
17739506COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORSMay 2022October 2024Abandon2920NoNo
17773098FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASESApril 2022March 2025Allow3500NoNo
17641485CLASS OF FUNCTIONAL MOLECULES TARGETING PROTEOLYSIS PATHWAYS, PREPARATION AND APPLICATION THEREOFMarch 2022February 2025Allow3600NoNo
17631765HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOFJanuary 2022April 2025Allow3801NoNo
17595745PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES COMPRISING NAPHTHOQUINONE DERIVATIVENovember 2021March 2025Abandon4001NoNo
17531216STABLE ANTIEMETIC EMULSIONSNovember 2021September 2024Allow3420NoNo
17611974Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent Against Gram-Negative BacteriaNovember 2021April 2025Abandon4110NoNo
17595470SUSTAINED RELEASE LOCAL ANESTHETIC HYDROGEL COMPOSITIONNovember 2021July 2025Allow4311NoNo
17612014TRANSITIONING PATIENTS TREATED FOR PULMONARY ARTERIAL HYPERTENSION TO SELEXIPAGNovember 2021June 2025Allow4320NoNo
17611544TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORSNovember 2021April 2025Allow4110NoNo
17521195BRM Targeting Compounds And Associated Methods Of UseNovember 2021June 2025Allow4321NoNo
17609034A PHARMACEUTICAL INTERMEDIATENovember 2021September 2024Allow3500NoNo
17607449SOLID FORM OF DIAMINOPYRIMIDINE COMPOUND OR HYDRATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFOctober 2021December 2024Allow3810NoNo
17606294IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVEOctober 2021April 2025Abandon4210NoNo
17605402USE OF COMPOUND IN PREPARATION OF DRUG FOR TREATING ATHEROSCLEROSISOctober 2021February 2025Abandon4001NoNo
17602408N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USEOctober 2021July 2024Allow3400NoNo
17602139ANTI-FUNGAL AGENTOctober 2021July 2024Allow3321NoNo
17602133CHRYSOPHAENTIN ANALOGS AND USE THEREOFOctober 2021April 2025Allow4211NoNo
17601372COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASEOctober 2021April 2025Abandon4201NoNo
17594128COMBINED USE OF A-NOR-5alpha ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUGOctober 2021March 2025Abandon4110NoNo
17600347METHODS OF USING MUSCARINIC ANTAGONISTS IN THE TREATMENT OF DEPRESSIONSeptember 2021May 2025Allow4320NoNo
17593969PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDSSeptember 2021December 2024Allow3910NoNo
17598122LOW-DOSE TRIPLE COMBINATION FORMULATIONSeptember 2021March 2025Abandon4101NoNo
17441153PHARMACEUTICAL COMPOSITIONSeptember 2021May 2025Abandon4411NoNo
17478152BYCYCLIC JAK INHIBITORS AND USES THEREOFSeptember 2021January 2025Allow4001NoNo
17440379MUSCLE BUILDING AGENTSeptember 2021April 2025Allow4310YesNo
17439012FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITORSeptember 2021March 2025Allow4411NoNo
17438479INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTIONSeptember 2021January 2024Allow2801YesNo
17435607PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONESeptember 2021July 2024Allow3500NoNo
17434353ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOFAugust 2021July 2025Allow4620NoNo
17310735COMPOUNDS AND METHODS OF DEUTERATED XANOMELINE FOR TREATING NEUROLOGICAL DISORDERSAugust 2021December 2024Abandon4010NoNo
17432842Pyrazolopyridine Compounds For IRE1 InhibitionAugust 2021March 2025Abandon4210NoNo
17431852TREATMENT OF PITT-HOPKINS SYNDROMEAugust 2021February 2025Abandon4210NoNo
17431447CRYSTALLINE FORM OF 1-(1-OXO-1,2-DIHYDROISOQUINOLIN-5-YL)-5-(TRIFLUOROMETHYL)-N-(2-(TRIFLUOROMETHYL)PYRIDIN-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE MONOHYDRATEAugust 2021December 2024Allow4010NoNo
17430549METHODS OF TREATING EPILEPSYAugust 2021August 2024Allow3601NoNo
17430248PROCESSES AND COMPOUNDSAugust 2021June 2025Allow4611NoNo
17430190PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND A KRASG12C INHIBITORAugust 2021February 2025Abandon4310NoNo
17444573CRYSTALLINE PRODUCTAugust 2021December 2024Abandon4010NoNo
17427708VINYLPYRIDINE CARBOXAMIDE COMPOUND AS PD-L1 IMMUNOMODULATORAugust 2021September 2024Allow3810NoNo
17427185PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITORJuly 2021August 2024Allow3600YesNo
17427357CRYSTALLINE FORM OF DI-P-TOLUOYL-L-TARTRATE OF UPADACITINIBJuly 2021July 2024Allow3610NoNo
17427395POLYVALENT DERIVATIVES OF EMOXYPINEJuly 2021January 2025Allow4110NoNo
17390631Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or VitiligoJuly 2021March 2025Abandon4320NoNo
17310347THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOFJuly 2021January 2025Abandon4210NoNo
17382624METHOD TO PREVENT AND TREAT ALOPECIA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERSJuly 2021October 2024Abandon3901NoNo
17424208COMPOSITION FOR THE TREATMENT OR PREVENTION OF INFECTIONS AND INFLAMMATIONSJuly 2021December 2024Abandon4110NoNo
17376311METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSISJuly 2021December 2024Abandon4210NoNo
17423432Antimicrobial Compounds and MethodsJuly 2021July 2025Allow4811NoNo
17422512NLRP3 MODULATORSJuly 2021March 2025Allow4411NoNo
17422650SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITYJuly 2021October 2024Abandon4001NoNo
17422635TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOFJuly 2021December 2024Abandon4110NoNo
17421179HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORSJuly 2021June 2024Allow3500NoNo
17421318N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Pneumonitis and Treatment of Pulmonary Function in Cystic FibrosisJuly 2021December 2024Allow4120NoNo
17419554IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOFJune 2021February 2025Abandon4401NoNo
17418442AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCERJune 2021April 2024Allow3400NoNo
17417071CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORSJune 2021November 2024Abandon4101NoNo
17416410KIF18A INHIBITORSJune 2021April 2025Allow4611NoNo
17416211NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOFJune 2021November 2024Abandon4101NoNo
17415696HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONSJune 2021September 2024Abandon3910NoNo
17345572METHODS FOR TREATING BRAIN METASTASISJune 2021February 2024Allow3220NoNo
17312321NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETOJune 2021March 2025Allow4521YesNo
17312371Methods of Treating InflammationJune 2021November 2024Abandon4210NoNo
17299890A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOFJune 2021March 2025Allow4511NoNo
17311249CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIAJune 2021July 2024Allow3710NoNo
17299999SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOFJune 2021June 2024Allow3701YesNo
17311240DEUTERATED ANALOGS OF ACETYL-LEUCINEJune 2021July 2024Allow3710NoNo
17309520SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOFJune 2021April 2025Allow4621NoNo
17298870MAP4K4 INHIBITORSJune 2021September 2024Allow3901NoNo
17298076SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAMEMay 2021May 2025Abandon4711NoNo
17334601REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERSMay 2021October 2024Abandon4001NoNo
17297439MITOCHONDRIAL ACTIVITY INHIBITORS TARGETING TUMORAL METABOLISMMay 2021March 2025Allow4521NoNo
17296165ER PROTEIN REGULATORS AND USE THEREOFMay 2021July 2024Abandon3801NoNo
17295231DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASESMay 2021October 2024Allow4120NoNo
17294915MODULATORS OF RAR-RELATED ORPHAN RECEPTORS (RORs)May 2021April 2025Allow4731YesNo
17294226NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOFMay 2021September 2024Allow4020NoNo
17293595COMPOSITION FOR PROMOTING HAIR GROWTH COMPRISING A GUANINE DERIVATIVEMay 2021May 2025Allow4830YesNo
17293742A CRYSTALLINE FORM OF 3- ((L-VALYL) AMINO) -1-PROPANESULFONIC ACIDMay 2021August 2024Allow3920NoNo
17316530CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIESMay 2021March 2025Allow4630NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SEITZ, ANTHONY JOSEPH.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
3
(100.0%)
Filing Benefit Percentile
0.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SEITZ, ANTHONY JOSEPH - Prosecution Strategy Guide

Executive Summary

Examiner SEITZ, ANTHONY JOSEPH works in Art Unit 1629 and has examined 127 patent applications in our dataset. With an allowance rate of 65.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner SEITZ, ANTHONY JOSEPH's allowance rate of 65.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SEITZ, ANTHONY JOSEPH receive 1.39 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SEITZ, ANTHONY JOSEPH is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +32.5% benefit to allowance rate for applications examined by SEITZ, ANTHONY JOSEPH. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 35.8% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 55.2% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 84.2% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.